ClinVar Miner

Submissions for variant NM_032043.3(BRIP1):c.2992_2995del (p.Lys998fs)

dbSNP: rs786203717
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 18
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000167141 SCV000217971 pathogenic Hereditary cancer-predisposing syndrome 2024-05-22 criteria provided, single submitter clinical testing The c.2992_2995delAAGA pathogenic mutation, located in coding exon 19 of the BRIP1 gene, results from a deletion of 4 nucleotides between positions 2992 and 2995, causing a translational frameshift with a predicted alternate stop codon. This mutation has been identified in early onset breast cancer and ovarian cancer patients (De Nicolo A et al. Clin. Cancer Res. 2008 Jul; 14(14):4672-80; Tedaldi G et al. Oncotarget 2017 Jul;8(29):47064-47075; Carter NJ et al. Gynecol Oncol. 2018 Dec;151(3):481-488). Functional analysis indicates that the premature truncation resulting from this alteration interferes with the stability of the protein and with its ability to interact with BRCA1 (De Nicolo A et al. Clin. Cancer Res. 2008 Jul; 14(14):4672-80). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation. As such, this alteration is interpreted as a disease-causing mutation.
Labcorp Genetics (formerly Invitae), Labcorp RCV000458808 SCV000547323 pathogenic Familial cancer of breast; Fanconi anemia complementation group J 2024-01-21 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Lys998Glufs*60) in the BRIP1 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 252 amino acid(s) of the BRIP1 protein. This variant is present in population databases (rs786203717, gnomAD 0.002%). This premature translational stop signal has been observed in individual(s) with breast cancer (PMID: 18628483, 26921362, 28423363). ClinVar contains an entry for this variant (Variation ID: 187416). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects BRIP1 function (PMID: 18628483, 20159562, 21127055, 21345144). This variant disrupts a region of the BRIP1 protein in which other variant(s) (p.Ser1070Glnfs*8) have been determined to be pathogenic (Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
GeneDx RCV000478533 SCV000564817 pathogenic not provided 2023-05-08 criteria provided, single submitter clinical testing Frameshift variant in the C-terminus predicted to result in protein truncation, as the last 252 amino acids are lost and replaced with 59 incorrect amino acids; Published functional studies demonstrate a damaging effect: impaired protein stability and interaction with BRCA1 (De Nicolo et al., 2008); Observed in individuals with breast, ovarian, or renal cancer (De Nicolo et al., 2008; Easton et al., 2016; Tedaldi et al., 2017; Carter et al., 2018; Yngvadottir et al., 2022); Not observed at a significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 21345144, 26921362, 20159562, 18628483, 20346647, 29368626, 31325073, 34426522, 35441217, 29922827, 33840814, 28423363, 30322717)
Color Diagnostics, LLC DBA Color Health RCV000167141 SCV000684241 likely pathogenic Hereditary cancer-predisposing syndrome 2022-03-06 criteria provided, single submitter clinical testing This variant deletes 4 nucleotides in exon 20 of the BRIP1 gene, creating a frameshift and premature translation stop signal in the last exon. This variant is expected to escape nonsense-mediated decay and be expressed as a truncated protein that lacks the functional domains involved in BRCA1-binding, DNA damage and replication stress responses and attenuation of DNA damage tolerance pathway (PMID: 11301010, 14983014, 20159562, 20173781, 22792074). A functional study has shown that this variant affects protein stability and impairs interaction with BRCA1 (PMID: 18628483). This variant has been reported in multiple individuals affected with breast cancer or from a high risk family (PMID: 18628483, 26921362, 28423363, 29368626, 31325073). One of these individuals also carried a pathogenic variant in the BRCA2 gene (PMID: 28423363). This variant has been observed in multiple individuals affected with breast cancer or having a family history of breast, ovarian or colorectal cancer (Color internal data). This variant has been identified in 5/282468 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of BRIP1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Likely Pathogenic.
Counsyl RCV000663176 SCV000786341 pathogenic Fanconi anemia complementation group J; Ovarian neoplasm 2018-04-13 criteria provided, single submitter clinical testing
Knight Diagnostic Laboratories, Oregon Health and Sciences University RCV000167141 SCV001448750 pathogenic Hereditary cancer-predisposing syndrome 2019-03-20 criteria provided, single submitter clinical testing
Revvity Omics, Revvity RCV001781517 SCV002017944 pathogenic Fanconi anemia complementation group J 2019-05-10 criteria provided, single submitter clinical testing
Sema4, Sema4 RCV000167141 SCV002533667 pathogenic Hereditary cancer-predisposing syndrome 2021-03-17 criteria provided, single submitter curation
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV002265649 SCV002547613 pathogenic Hereditary breast ovarian cancer syndrome 2022-05-04 criteria provided, single submitter clinical testing Variant summary: BRIP1 c.2992_2995delAAGA (p.Lys998GlufsX60) results in a premature termination codon causes a truncation of the encoded protein which is a commonly known mechanism for disease (De Nicolo_2008). Truncations downstream of this position have been observed at our laboratory and reported in association with other BRIP1-related cancers in the HGMD database. The variant allele was found at a frequency of 1.6e-05 in 251076 control chromosomes. c.2992_2995delAAGA has been reported in the literature among individuals with a variety of BRIP1-associated cancers such as breast/ovarian and AML (example, De Nicolo_2008, Tedaldi_2017, Carter_2018, Weber-Lassalle_2018, Wagener_2021). These data indicate that the variant is likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function (Di Nicolo_2008). The most pronounced variant effect impairs BRIP1 function and its ability to interact with BRCA1. Eight clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
MGZ Medical Genetics Center RCV002288764 SCV002579452 pathogenic Familial cancer of breast 2021-08-10 criteria provided, single submitter clinical testing
Myriad Genetics, Inc. RCV002288764 SCV004019355 pathogenic Familial cancer of breast 2023-02-28 criteria provided, single submitter clinical testing This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.
Institute of Human Genetics, University of Leipzig Medical Center RCV002288764 SCV004175999 pathogenic Familial cancer of breast 2024-05-22 criteria provided, single submitter clinical testing Criteria applied: PVS1,PS3,PS4,PM2_SUP
Baylor Genetics RCV002288764 SCV004214739 pathogenic Familial cancer of breast 2023-09-26 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000478533 SCV004220715 pathogenic not provided 2023-04-12 criteria provided, single submitter clinical testing This frameshift variant alters the translational reading frame of the BRIP1 mRNA and causes the premature termination of BRIP1 protein synthesis. The frequency of this variant in the general population, 0.000023 (3/129046 chromosomes, http://gnomad.broadinstitute.org), is consistent with pathogenicity. In the published literature, the variant has been reported in affected individuals with breast and/or ovarian cancer (PMID: 18628483 (2008), 26921362 (2016), 28423363 (2017), 29368626 (2018), 30322717 (2018), and 31325073 (2019)), as well as in an individual with acute myeloid leukemia (PMID: 33840814 (2021)). One functional study on transfected cells showed that the truncation interferes with the stability of the protein and with its ability to interact with BRCA1 (PMID: 18628483 (2008)), while another demonstrated reduced protein expression and BRCA1 binding disruption (PMID: 21345144 (2011)). Based on the available information, this variant is classified as pathogenic.
Genomic Medicine Lab, University of California San Francisco RCV002288764 SCV004847121 pathogenic Familial cancer of breast 2023-12-11 criteria provided, single submitter clinical testing
CeGaT Center for Human Genetics Tuebingen RCV000478533 SCV005075166 pathogenic not provided 2024-06-01 criteria provided, single submitter clinical testing BRIP1: PVS1:Strong, PM2, PS3:Moderate, PS4:Moderate
Department of Pediatric Oncology, Hematology and Clinical Immunology, University Clinics Duesseldorf RCV000167141 SCV001482294 uncertain significance Hereditary cancer-predisposing syndrome flagged submission research
Medical Genetics Laboratory, Umraniye Training and Research Hospital, University of Health Sciences RCV001554295 SCV001774870 pathogenic Breast carcinoma 2021-08-09 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.